Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biofrontera Inc (NQ: BFRI )

0.4648 -0.0052 (-1.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,263
Open 0.4679
Bid (Size) 0.4601 (11)
Ask (Size) 0.4767 (1)
Prev. Close 0.4700
Today's Range 0.4520 - 0.4799
52wk Range 0.3703 - 3.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biofrontera Inc. Announces U.S. Patent Issued for Photodynamic Therapy Protocol with Reduced Side Effects
Via ACCESSWIRE
Why Is Biolase (BIOL) Stock Down 13% Today?
Biolase (BIOL) stock is taking a beating on Friday following the release of its earnings report for the first quarter of 2023. 
Via InvestorPlace

Performance

YTD
-45.00%
-45.00%
1 Month
-21.22%
-21.22%
3 Month
-38.02%
-38.02%
6 Month
-55.31%
-55.31%
1 Year
-83.80%
-83.80%

More News

Read More
Why Is Assure (IONM) Stock Down 36% Today?
Via InvestorPlace
Why Is Getaround (GETR) Stock Up 104% Today?
Via InvestorPlace
Earnings Scheduled For May 12, 2023
Via Benzinga
Biofrontera: Q1 Earnings Insights
Via Benzinga
Biofrontera Inc. Reports First Quarter 2023 Financial Results and Provides a Business Update
Via ACCESSWIRE
Biofrontera Inc. Announces Resignation of CEO
Via ACCESSWIRE
BFRI Stock Earnings: Biofrontera Misses EPS, Revenue Estimates
Via InvestorPlace
Biofrontera Earnings Preview
Via Benzinga
Biofrontera Inc. Announces New Secured Line of Credit up to $6.5 Million
Via ACCESSWIRE
Biofrontera Collaborates with The Skin Cancer Foundation to Raise Awareness of Skin Cancer Prevention
Via ACCESSWIRE
Biofrontera Inc. to Report First Quarter 2023 Financial Results on May 12, 2023
Via ACCESSWIRE
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
Via ACCESSWIRE
Biofrontera Inc. to Attend 2023 American Academy of Dermatology Annual Meeting
Via ACCESSWIRE
Biofrontera's Earnings Outlook
Via Benzinga
Biofrontera Inc. Makes Transformative Investment in Its' Dermatology Salesforce
Via ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Why Sarepta Therapeutics Shares Are Trading Lower By Around 19%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CORRECTING AND REPLACING: Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Biofrontera Inc. Reports Fourth Quarter and Record Full-year 2022 Financial Results
Via ACCESSWIRE
Earnings Scheduled For March 8, 2023
Via Benzinga
Biofrontera, Inc. to Present at the 35th Annual ROTH Conference on March 13, 2023
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.